Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ferro-lipo (ferric ammonium citrate)
- Development stage
- Phase 1
- Lead developer
- AFT Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ferro-Lipo is a liposomal oral iron supplement developed by AFT Pharmaceuticals for the treatment of iron deficiency anaemia. It utilizes a lecithin-based Liposhell technology to encapsulate ferric ammonium citrate, which enhances the absorption of iron and improves gastrointestinal tolerability compared to conventional iron salts. By delivering iron directly to the body's stores and the transferrin-mediated transport system, it supports hemoglobin synthesis and red blood cell formation. The product is typically provided in a gel sachet formulation.
- Brand names
- Ferro-Lipo
- Other names
- liposomal ferric ammonium citrate
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on ferro-lipo (ferric ammonium citrate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ferro-lipo (ferric ammonium citrate).